ISCO to Present New Data From Parkinson's Disease Program

New Post Public Reply Private Reply Replies (0) Message Board
StockBull1 StockMasterTalk #3978
ISCO to Present New Data From Parkinson's Disease Program at the American Neurological Association 2013 Annual Meeting.
CARLSBAD, CA--(Marketwired - Sep 25, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) ( www.internationalstemcell.com ), a California-based biotechnology company developing novel stem cell based therapies, announced today that its chief scientific officer, Dr. Ruslan Semechkin, will present the latest results from its Parkinson's disease program at the American Neurological Association's 2013 Annual Meeting October 13 - 15, 2013 in New Orleans, LA.

Conducted in collaboration with the Sanford Burnham Medical Research Institute, the presentation will include new data and results from ISCO's first primate study, including an outline of neural stem cells' unique mechanism of action, data on the fate of the cells and a detailed analysis of the primate's immune response to the implantation. The presentation will be at the following session:

Date: Monday, October 14, 2013
Time: 11:00 am - 7:00 pm
Title: The Use of Neural Stem Cells for the Treatment of Parkinson's Disease in a Non-Human Primate Model

ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (1) differentiate into dopaminergic neurons and (2) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new and revolutionary opportunity for the treatment of Parkinson's disease, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( www.lifelinecelltech.com ), and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( www.lifelineskincare.com ). More information is available at www.internationalstemcell.com .

To receive ongoing corporate communications via email, visit:  http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit:  www.facebook.com/InternationalStemCellCorporation and  www.twitter.com/intlstemcell

Contact:


International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383 
Email:  ir@intlstemcell.com

Dr. Ruslan Semechkin
Vice President, R&D
Phone: 760-940-6383
Email:  ras@intlstemcell.com
http://finance.yahoo.com/news/international-s...00724.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 487

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 513

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 46

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 189

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 347

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

Updated Category News Views 56

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone

Updated Category News Views 62

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 95

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 345

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading

Top 5 Most Recently Viewed Articles

EssilorLuxottica Reports Share Capital and Voting Rights Update

Updated Category News Views 214

Overview of EssilorLuxottica's Share Capital EssilorLuxottica, a prominent global leader in eyewear design, manufacture, and distribution, provides a detailed disclosure of its outstanding share capital and voting rights as of a recent date. This information is essential for shareholders and market watchers to understand the company's governance and share structure. Share...

Continue Reading
WM Technology, Inc. Faces Class Action Lawsuit with SEC Fallout

Updated Category News Views 208

WM Technology, Inc. Faces Legal Challenges Recently, a class action lawsuit has arisen against WM Technology, Inc. (NASDAQ: MAPS), a pivotal player in the online cannabis marketplace. The Pomerantz Law Firm has initiated this legal action on behalf of affected investors. As the case unfolds, individuals who believe they have been impacted by the company's actions are...

Continue Reading
EVgo Targets 2026 for Profitable Future Amid Challenges

Updated Category News Views 554

EVgo Overview EVgo Inc. (NASDAQ: EVGO) has faced recent fluctuations in share price following the announcement of its fiscal third-quarter results. The company operates one of the largest public electric vehicle charging networks in the United States, and it has been navigating a challenging landscape in the EV sector. Financial Performance Analysis In its latest report,...

Continue Reading
CNX Resources Corporation Reveals Financial Updates and Call Schedule

Updated Category News Views 126

CNX Resources Corporation Financial Results Announcement CNX Resources Corporation (NYSE: CNX) is set to unveil its financial results for the fourth quarter of 2025. This important event will take place at 6:45 a.m. Eastern Time on an upcoming Thursday. During this announcement, CNX intends to release a concise press statement that will include essential documents linking...

Continue Reading
Nvidia's Revolutionary AI Dominance and Future Outlook

Updated Category News Views 193

Understanding AI and Nvidia's Impact Since the dawn of the internet, investors have seen many trends come and go, but few have been as impactful as the artificial intelligence (AI) revolution. This groundbreaking technology has sparked interest among both seasoned professionals and everyday investors, all eager to explore its immense potential. It’s estimated that AI...

Continue Reading